Restricted accessResearch articleFirst published online 2026
Prevalence of Staphylococcus aureus skin colonization and its correlation with serum interleukin-22 levels,disease severity,and body mass index in patients with psoriasis
There is limited data regarding the correlation between interleukin-22 (IL-22) levels and psoriasis severity or body mass index (BMI). In addition, few studies have investigated the prevalence of different toxigenic strains of Staphylococcus aureus in psoriasis and their association with disease severity and BMI. This cross-sectional study examined the prevalence of S. aureus skin colonization in patients with psoriasis and its correlation with serum IL-22 levels, disease severity, and BMI. S. aureus isolates were identified, and their toxigenic strains were detected by polymerase chain reaction. Serum IL-22 levels were measured using an enzyme-linked immunosorbent assay. A majority of patients (60.2%) demonstrated S. aureus colonization in both lesional and nonlesional skin. In lesional skin, 45.2% of patients were colonized by toxigenic strains, with the SEB strain being the most prevalent (24.7% cases). In contrast, 47.3% of patients showed colonization by nontoxigenic strains in nonlesional skin. Colonization by toxigenic strains was significantly higher in lesional skin, whereas colonization by nontoxigenic strains was markedly higher in nonlesional skin (p = 0.001 for each). Both psoriasis severity and pruritus intensity were significantly greater among patients colonized with toxigenic strains (p = 0.001 each). Mean serum IL-22 levels were also significantly higher in patients with severe disease and pruritus (p = 0.001 each). Moreover, serum IL-22 levels showed strong positive correlations with BMI, psoriasis severity, and pruritus severity (p = 0.002, 0.0001, and 0.0001, respectively). This study highlights significant associations between S. aureus colonization, particularly the toxigenic strain SEB and psoriasis severity, serum IL-22 levels, and BMI. Further large-scale studies are warranted to validate these findings.
BarrosGDuranPVeraI, et al. Exploring the links between obesity and psoriasis: a comprehensive review. Int J Mol Sci2022; 23: 7499.
4.
HölskenSKreftingFSchedlowskiM, et al. Common fundamentals of psoriasis and depression. Acta Derm Venereol2021; 101: adv00609.
5.
RendonASchäkelK.Psoriasis pathogenesis and treatment. Int J Mol Sci2019; 20: 1475.
6.
UppalaRTsoiLCHarmsPW, et al. “Autoinflammatory psoriasis” genetics and biology of pustular psoriasis. Cell Mol Immunol2021; 18: 307–317.
7.
WolkKWitteEWallaceE, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol2006; 36(5): 1309–1323.
8.
BosJDde RieMATeunissenMB, et al. Psoriasis: dysregulation of innate immunity. Br J Dermatol2005; 152: 1098–1107.
9.
Carmona-CruzSOrozco-CovarrubiasLSáez-de-OcarizM.The human skin microbiome in selected cutaneous diseases. Front Cell Infect Microbiol2022; 12: 834135.
10.
MazurMTomczakHLodygaM, et al. The microbiome of the human skin and its variability in psoriasis and atopic dermatitis. Postepy Dermatol Alergol2021; 38: 205–209.
11.
GaoZTsengCHStroberBE, et al. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One2008; 3(7): e2719.
12.
NgCYHuangYHChuCF, et al. Risks for Staphylococcus aureus colonization in patients with psoriasis: a systematic review and meta-analysis. Br J Dermatol2017; 177(4): 967–977.
13.
TomiNSKränkeBAbererE.Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol2005; 53(1): 67–72.
14.
AtefiNNoorbakhshSGhavidel DarestaniS, et al. The rise of staphylococcal super antigens in psoriatic patients: a case-control study. Jundishapur J Microbiol2014; 7(5): e9912.
15.
CurryJLQinJZRobinsonJ, et al. Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system. Arch Pathol Lab Med2003; 127(3): 289–296.
16.
BalciDDDuranNOzerB, et al. High prevalence of Staphylococcus aureus cultivation and superantigen production in patients with psoriasis. Eur J Dermatol2009; 19(3): 238–242.
17.
FloretD.Clinical aspects of streptococcal and staphylococcal toxinic diseases. Arch Pediatr2001; 8(4): 762s–768s.
18.
BackertIKoralovSBWirtzS, et al. STAT3 activation in Th17 and Th22 cells controls IL-22-mediated epithelial host defense during infectious colitis. J Immunol2014; 193: 3779–379.
19.
SovranBLoonenLMLuP, et al. IL-22-STAT3 pathway plays a key role in the maintenance of ileal homeostasis in mice lacking secreted mucus barrier. Inflamm Bowel Dis2015; 21: 531–542.
20.
ShenJFangYZhuH, et al. Plasma interleukin-22 levels are associated with prediabetes and type 2 diabetes in the Han Chinese population. J Diabetes Investig2018; 9(1): 33–38.
21.
JassimHABakirSSAlhamdiKI, et al. Polymerase chain reaction (PCR) for detection superantigenicity of Staphylococcus aureus isolated from psoriatic patients. Int J Microbiol Res Rev2013; 1(1): 022–027.
22.
FinlayAY.Current severe psoriasis and the rule of tens. Br J Dermatol2005; 152(5): 861–867.
23.
AugustinMLangenbruchAGutknechtM, et al. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. Br J Dermatol2018; 179(6): 1385–1391.
24.
ReichAHeisigMPhanNQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol2012; 92(5): 497–501.
25.
WHO: Physical Status: The Use and Interpretation of Anthropometry: Report of a World Health Organization (WHO) Expert Committee. Geneva, Switzerland: World Health Organization, https://www.who.int/publications/i/item/9241208546 (1995, accessed 30 October 2023).
26.
PuzenatEBronsardVPreyS, et al. What are the best outcome measures for assessing plaque psoriasis severity? a systematic review of the literature. J Eur Acad Dermatol Venereol2010; 2: 10–16.
27.
ShabgahAGNavashenaqJGShabgahOG, et al. Interleukin-22 in human inflammatory diseases and viral infections. Autoimmun Rev2017; 16(12): 1209–1218.
28.
ChangHWYanDSinghR, et al. Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome2018; 6(1): 154.
29.
RadaschinDSTatuAIancuAV, et al. The contribution of the skin microbiome to psoriasis pathogenesis and its implications for therapeutic strategies. Medicina (Kaunas)2024; 60(10): 1619.
30.
LewisDJChanWHHinojosaT, et al. Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: a review. Clin Dermatol2019; 37(2): 160–166.
31.
FryLBakerBS.Triggering psoriasis: the role of infections and medications. Clin Dermatol2007; 25(6): 606–615.
32.
KolataJBKühbandnerILinkC, et al. The Fall of a Dogma? Unexpected High T-Cell Memory Response to Staphylococcus aureus in Humans. J Infect Dis2015; 212(5): 830–838.
33.
AlekseyenkoAVPerez-PerezGIDe SouzaA, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome2013; 1(1): 31.
34.
TettAPasolliEFarinaS, et al. Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. NPJ Biofilms Microbiomes2017; 3: 14.
35.
LiuSHYuHYChangYC, et al. Host characteristics and dynamics of Staphylococcus aureus colonization in patients with moderate-to-severe psoriasis before and after treatment: a prospective cohort study. J Am Acad Dermatol2019; 81(2): 605–607.
36.
FahlénAEngstrandLBakerBS, et al. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res2012; 304(1): 15–22.
37.
Willerslev-OlsenAKrejsgaardTLindahlLM, et al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood2016; 127(10): 1287–1296.
38.
AgerholmRRizkJViñalsMT, et al. STAT3 but not STAT4 is critical for γδT17 cell responses and skin inflammation. EMBO Rep2019; 20(11): e48647.
39.
FouadNMostafaFSoltanM, et al. Skin colonization of Staphylococcus aureus harboring superantigen toxin genes and its correlation with serum IL-22 level in psoriasis patients. Egypt J Immunol2022; 29(4): 94–105.
40.
El FerezliJJenbazianLRubeizN, et al. Streptococcus sp. and Staphylococcus aureus isolates from patients with psoriasis possess genes that code for toxins (Superantigens): clinical and therapeutic implications. Immunopharmacol Immunotoxicol2008; 30(2): 195–205.
41.
Santiago-RodriguezTMLe FrançoisBMacklaimJM, et al. The skin microbiome: current techniques, challenges, and future directions. Microorganisms2023; 11(5): 1222.
42.
OgaiKNagaseSMukaiK, et al. A comparison of techniques for collecting skin microbiome samples: swabbing versus tape-stripping. Front Microbiol2018; 9: 2362.
43.
BergmanRNVan CittersGWMittelmanSD, et al. Central role of the adipocyte in the metabolic syndrome. J Investig Med2001; 49(1): 119–126.
44.
MakkiKFroguelPWolowczukI.Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm2013; 139239.
45.
OlsenKDanielsenKWilsgaardT, et al. Obesity and Staphylococcus aureus nasal colonization among women and men in a general population. PLoS One2013; 8(5): e63716.
46.
PawlowskiBNowakJBorkowskaB, et al. Human body morphology, prevalence of nasopharyngeal potential bacterial pathogens and immunocompetence handicap principal. Am J Hum Biol2014; 26: 305–310.
47.
Botelho-NeversEBerthelotPVerhoevenPO, et al. Are the risk factors associated with Staphylococcus aureus nasal carriage in patients the same than in healthy volunteers? Data from a cohort of patients scheduled for orthopedic material implantation. Am J Infect Control2014; 42: 1121–1123.
48.
BefusMLowyFDMikoBA, et al. Obesity as a determinant of Staphylococcus aureus colonization among inmates in maximum security prisons in New York State. Am J Epidemiol2015; 182(6): 494–502.
49.
GöçmenJSŞahinerNKoçakM, et al. PCR investigation of panton-valentine leukocidin, enterotoxin, exfoliative toxin, and Agr genes in Staphylococcus aureus strains isolated from psoriasis patients. Turk J Med Sci2015; 45(6): 1345–1352.
50.
DengLCostaFBlakeKJ, et al. S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis. Cell2023; 186(24): 5375–5393.e25.
51.
GalloRLHorswillAR.Staphylococcus aureus: the bug behind the itch in atopic dermatitis. J Invest Dermatol2024; 144(5): 950–953.
52.
ParkHYKimCRHuhIS, et al. Staphylococcus aureus colonization in acute and chronic skin lesions of patients with atopic dermatitis. Ann Dermatol2013; 25(4): 410–416.
53.
ChenLLiJZhuW, et al. Skin and gut microbiome in psoriasis: gaining insight into the pathophysiology of it and finding novel therapeutic strategies. Front Microbiol2020; 11: 589726.
54.
QuanCChenXYLiX, et al. Psoriatic lesions are characterized by higher bacterial load and imbalance between cutibacterium and corynebacterium. J Am Acad Dermatol2020; 82(4): 955–961.
55.
MulcahyMELeechJMRenauldJC, et al. Interleukin-22 regulates antimicrobial peptide expression and keratinocyte differentiation to control Staphylococcus aureus colonization of the nasal mucosa. Mucosal Immunol2016; 9(6): 1429–1441.
56.
ChanLCChailiSFillerSG, et al. Nonredundant roles of interleukin-17A (IL-17A) and IL-22 in murine host defense against cutaneous and hematogenous infection due to methicillin-resistantStaphylococcus aureus. Infect Immun2015; 83(11): 4427–4437.
57.
Van BelleABde HeuschMLemaireMM, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol2012; 188(1): 462–469.
58.
NiebuhrMMainardyJHeratizadehA, et al. Staphylococcal exotoxins induce interleukin 22 in human th22 cells. Int Arch Allergy Immunol2014; 165(1): 35–39.
59.
WawrzyckiBPietrzakAGrywalskaE, et al. Interleukin-22 and its correlation with disease activity in plaque psoriasis. Arch Immunol Ther Exp (Warsz)2019; 67(2): 103–108.
60.
VoglisSMoosSKloosL, et al. Regulation of IL-22BP in psoriasis. Sci Rep2018; 8(1): 5085.
61.
MartinJCWolkKBeriouG, et al. Limited presence of IL-22 binding protein, a natural IL-22 inhibitor, strengthens psoriatic skin inflammation. J Immunol2017; 198(9): 3671–3678.
62.
ZenewiczLA.IL-22 binding protein (IL-22BP) in the regulation of IL-22 biology. Front Immunol2021; 12: 766586.
63.
CordoroKMHitraya-LowMTaravatiK, et al. Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol2017; 77(3): 417-424.
64.
Guttman-YasskyEBrunnerPMand Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double blind, phase 2a trial. J Am Acad Dermatol2018; 78(5): 872–881.e6.
65.
HerderCKannenbergJMCarstensen-KirbergM, et al. Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. Cardiovasc Diabetol2017; 16(1): 17.
66.
GuJZhouPLiuY, et al. Down-regulating Interleukin-22/Interleukin-22 binding protein axis promotes inflammation and aggravates diet-induced metabolic disorders. Mol Cell Endocrinol2022; 557: 111776.
67.
FujitaH.The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci2013; 72(1): 3–8.
